Opportunity assessment and market attractiveness for one of the top 10 pharmaceutical major

  • Benchmarked therapeutic areas with high clinical and market potential

  • Developed potential market scenarios based on client needs


CLIENT CHALLENGES
  • One of the top 10 pharmaceutical majors wanted to determine market attractiveness and assess opportunities for its asset being developed for CLL, MCL and WM
  • Key challenges were:
    • Benchmark therapeutic areas being based on diverse parameters involving clinical, regulatory and market assessment
    • Building a 360-degree view of the market by combining market sizing with adoption share
    • Market attractiveness based on regulatory/NCCN approval, adoption, reimbursement and market access
    • Understanding niche therapeutic areas
OUR APPROACH
  • Competitive analysis:
    • Identified key competitors within each indication and patient population
    • Conducted a detailed comparison of the client’s asset and each asset in the pipeline
    • Scored the client’s asset in terms of clinical attractiveness within each indication
  • Market sizing:
    • Adopted a bottom-up sizing approach – from disease prevalence to the diagnosed and drug-treated population in major markets (the US and EU5)
  • Key differentiator analysis:
    • Generated revenue estimations in each indication based on adoption share
    • Factored in the differences for adoption share and launch timelines and estimated duration of therapies
IMPACT DELIVERED
  • Advised on the attractiveness of the indications among CLL, MCL and WM
  • Created market scenarios based on regulatory approvals, reimbursement and market access
  • Built a dashboard to enable the client to customise results based on assumptions
Thank you for sharing your details

Your file will start downloading automatically

If it does not download within 1 minute,

Share this on

What we have done

Product launch strategy for European biopharmaceutical company
What we are proud of

>50%

savings in staffing costs

25%

increase in outreach

Competitor benchmarking and performance gap analysis for a leading European medical device player
What we are proud of

>50%

savings in staffing costs

25%

increase in outreach

Assessing viability of entering the NSCLC market
What we are proud of

>50%

savings in staffing costs

25%

increase in outreach

Assessment of GCC pharmaceutical market for a global European pharma major
What we are proud of

>50%

savings in staffing costs

25%

increase in outreach

Supplier assessment and industry benchmarking for a global top 10 pharmaceutical company
What we are proud of

>50%

savings in staffing costs

25%

increase in outreach

Research on a multiple sclerosis drug with help from global neurologists
What we are proud of

>50%

savings in staffing costs

25%

increase in outreach

Procurement in non-Food FMCG Industry
What we are proud of

>50%

savings in staffing costs

25%

increase in outreach